CNS Pharmaceuticals, Inc.
CNSP
$6.66
$0.152.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.56% | 14.00% | 23.58% | 17.66% | -13.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.72% | -2.57% | -10.23% | -21.01% | -8.26% |
| Operating Income | 22.72% | 2.57% | 10.23% | 21.01% | 8.26% |
| Income Before Tax | 23.37% | 3.22% | 10.59% | 21.18% | 8.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.37% | 3.22% | 10.59% | 21.18% | 8.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.37% | 3.22% | 10.59% | 21.18% | 8.36% |
| EBIT | 22.72% | 2.57% | 10.23% | 21.01% | 8.26% |
| EBITDA | 22.73% | 2.57% | 10.23% | 21.01% | 8.26% |
| EPS Basic | 56.53% | -- | -- | -- | -- |
| Normalized Basic EPS | 56.53% | -- | -- | -- | -- |
| EPS Diluted | 56.47% | -- | -- | -- | -- |
| Normalized Diluted EPS | 56.53% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 3,303.55% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 3,303.55% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |